Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cell surface as monomers, homodimers and heterodimers with EGFR/HER3. The therapeutic antibody trastuzumab, an approved therapy for HER2+ breast cancer, cannot block ligand-induced HER2 heterodimers, suggesting it canno...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ghosh, Ritwik, Narasanna, Archana, Wang, Shizhen Emily, Liu, Shuying, Chakrabarty, Anindita, Balko, Justin M., González-Angulo, Ana María, Mills, Gordon B., Penuel, Elicia, Winslow, John, Sperinde, Jeff, Dua, Rajiv, Pidaparthi, Sailaja, Mukherjee, Ali, Leitzel, Kim, Kostler, Wolfgang J., Lipton, Allan, Bates, Michael, Arteaga, Carlos L.
Format:	Artigo
Language:	Inglês
Published:	2011
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3221734/ https://ncbi.nlm.nih.gov/pubmed/21324925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-1872
Tags:	Add Tag No Tags, Be the first to tag this record!

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

Similar Items